- Home
- VVV vs CYTK Comparison
VVV vs CYTK Comparison
Compare VVV & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VVV
- CYTK
- Stock Information
- Founded
- VVV 1866
- CYTK 1997
- Country
- VVV United States
- CYTK United States
- Employees
- VVV N/A
- CYTK N/A
- Industry
- VVV Major Chemicals
- CYTK Biotechnology: Pharmaceutical Preparations
- Sector
- VVV Industrials
- CYTK Health Care
- Exchange
- VVV Nasdaq
- CYTK Nasdaq
- Market Cap
- VVV 4.7B
- CYTK 5.6B
- IPO Year
- VVV 2016
- CYTK 2004
- Fundamental
- Price
- VVV $33.01
- CYTK $31.70
- Analyst Decision
- VVV Buy
- CYTK Buy
- Analyst Count
- VVV 11
- CYTK 19
- Target Price
- VVV $42.55
- CYTK $77.33
- AVG Volume (30 Days)
- VVV 1.7M
- CYTK 2.3M
- Earning Date
- VVV 05-08-2025
- CYTK 05-06-2025
- Dividend Yield
- VVV N/A
- CYTK N/A
- EPS Growth
- VVV 56.15
- CYTK N/A
- EPS
- VVV 2.05
- CYTK N/A
- Revenue
- VVV $1,674,400,000.00
- CYTK $19,218,000.00
- Revenue This Year
- VVV $9.14
- CYTK $55.84
- Revenue Next Year
- VVV $14.43
- CYTK $646.96
- P/E Ratio
- VVV $16.00
- CYTK N/A
- Revenue Growth
- VVV 9.56
- CYTK 412.21
- 52 Week Low
- VVV $31.02
- CYTK $31.67
- 52 Week High
- VVV $48.27
- CYTK $68.44
- Technical
- Relative Strength Index (RSI)
- VVV 41.43
- CYTK 29.83
- Support Level
- VVV $31.59
- CYTK $31.67
- Resistance Level
- VVV $35.17
- CYTK $43.51
- Average True Range (ATR)
- VVV 1.07
- CYTK 1.97
- MACD
- VVV 0.01
- CYTK -0.78
- Stochastic Oscillator
- VVV 38.80
- CYTK 0.21
About VVV Valvoline Inc.
Valvoline Inc produces, markets, and sells automotive maintenance products, particularly lubricants, to retail outlets installers, and customers. The company offers various products such as engine oil, heavy-duty engine oil, motorcycle oil, grease and brake fluid, and others. Geographically, the majority of the revenue is generated from the United States of America.
About CYTK Cytokinetics Incorporated
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.